We propose to establish the Center for Hemoglobin Research in Minorities (CHaRM), which will build on and synergize with the existing HBCU Research Scientist Program. The CHaRM's ultimate goal is to provide and to improve the necessary research infrastructure, while augmenting science education and research training for pre- and postdoctoral students, and strengthening scientific faculty research and career development. We will establish a NHLBI Research Center at Howard University that will augment and strengthen research capabilities and resources in biomedical and behavioral research related to heart, lung and blood diseases and disorders in minority populations. This proposal will build on previously developed Research Scientist Program at Howard University's Center for Sickle Cell Disease (CSCD) that was supported by NHLBI from 1999 to 2012 and recently received the P30 award for Phase I of this program.
In Aim 1, we will establish a center of excellence for the study of hemoglobinopathies, iron metabolism, and oxygen sensing. We will recruit an external mid-level or senior investigator who will serve as program director and retain the existing recently hired junior faculty. We will also establish a steering committee, an external advisory board and use an external evaluator for the program.
In Aim 2, we will establish an administrative core to provide support and conduct training activities.
In Aim 3, we will educate and train minority students and fellows by providing research and laboratory experience, developing additional scientific curricula, facilitate scientific exchange and conduct seminars.
In Aim 4, we will expand and enhance the research advances made by the Howard University Research Scientist Program in clinical and molecular aspects of sickle cell disease, iron metabolism, and oxygen sensing.
In Aim 5, we will enhance and facilitate existing collaborations within and outside of Howard University and share existing resources. The underlying themes of the research we envision are to reduce health disparities and to enhance excellence in research into heart, lung and blood diseases at Howard University. In pursuit of the scientific and educational goals, an integral part of the program will be to obtain additional research support from NIH and other sources.

Public Health Relevance

The mission of the CHaRM is relevant to public Health because it is aimed at reducing health disparities and enhancing excellence into heart, lung and blood diseases at Howard University. The proposed activities are relevant to the NIH mission that pertains to reduce vulnerability of the population to chronic and infectious diseases and to train and educate minority students and medical fellows.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL118006-02
Application #
8725226
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Lee, Albert
Project Start
2013-08-22
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Howard University
Department
Type
Schools of Medicine
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20059
Khaibullina, Alfia; Adjei, Elena A; Afangbedji, Nowah et al. (2018) RON kinase inhibition reduces renal endothelial injury in sickle cell disease mice. Haematologica 103:787-798
Ivanov, Andrey; Lin, Xionghao; Ammosova, Tatiana et al. (2018) HIV-1 Tat phosphorylation on Ser-16 residue modulates HIV-1 transcription. Retrovirology 15:39
Jerebtsova, Marina; Saraf, Santosh L; Soni, Simran et al. (2018) Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia. Am J Hematol 93:E107-E109
Jerebtsova, Marina; Saraf, Santosh L; Lin, Xionghao et al. (2018) Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis. Am J Hematol 93:E45-E47
Dai, Yan; Sangerman, Jose; Nouraie, Mehdi et al. (2017) Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer. Am J Hematol 92:E10-E11
Darbari, Deepika S; Vaughan, Kathleen J; Roskom, Katherine et al. (2017) Central sensitization associated with low fetal hemoglobin levels in adults with sickle cell anemia. Scand J Pain 17:279-286
Lin, Xionghao; Ammosova, Tatyana; Kumari, Namita et al. (2017) Protein Phosphatase-1 -targeted Small Molecules, Iron Chelators and Curcumin Analogs as HIV-1 Antivirals. Curr Pharm Des 23:4122-4132
Sergueeva, Adelina; Miasnikova, Galina; Shah, Binal N et al. (2017) Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia. Haematologica 102:e166-e169
Whitesell, P L; Owoyemi, O; Oneal, P et al. (2016) Sleep-disordered breathing and nocturnal hypoxemia in young adults with sickle cell disease. Sleep Med 22:47-49
Huang, Hanxia; Konduru, Krishnamurthy; Solovena, Veronica et al. (2016) Therapeutic potential of the heme oxygenase-1 inducer hemin against Ebola virus infection. Curr Trends Immunol 17:117-123

Showing the most recent 10 out of 45 publications